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Parents should be offered an antenatal appointment with a paediatric service to discuss NAS and implications for care of the baby, including length of stay, monitoring and potential for medication.
Labour and birth
Routine management of labour and birth should occur. The use of antagonistic drugs such as Naloxone (Narcan) are contraindicated in the neonatal period, including for resuscitation if there has been maternal opioid use during pregnancy.
Monitoring
Use of a validated assessment tool (Finnegan score) helps to determine which babies have NAS and should be used to monitor and record symptoms of withdrawal.
Supporting breastfeeding
In most cases, breastfeeding should be encouraged and supported if it is the mother's choice. The severity of NAS and requirement for medication may be reduced by the provision of breast milk.
Setting for care
Initial care may be provided on the postnatal ward with the mother. Symptomatic babies require a higher level of care and this may require transfer to a special care nursery for closer observation and assessment.
Choices of treatment
Non-pharmacological management (supportive therapy) is the first line of treatment for all babies exposed to maternal substance use in pregnancy. If medication is required for withdrawal, morphine is the drug of choice for opioid withdrawal and phenobarbitone should be prescribed for nonopioid withdrawal.
Discharge planning
Discharge planning and follow-up should involve a multidisciplinary approach including the Paediatrician, Social Worker, GP, Child Health, Indigenous Health and other appropriate community supports.
Introduction
NAS is more common in babies born to opioid dependent women particularly methadone, heroin and buprenorphine. 1 It may also occur in babies following prolonged post-natal drug exposure e.g. postoperative analgesia.
This guideline is applicable to neonatal drug withdrawal from any substance, licit or illicit.
Definition
Neonatal abstinence syndrome (NAS) is a syndrome of drug withdrawal with non specific signs and symptoms that may occur in babies following in-utero drug exposure. 1
Substances used or misused
A large variety of substances may be used or misused by women of childbearing age. 2 Many are known to cause neonatal behaviour consistent with drug withdrawal. In-utero fetal exposure to the following major classes of drugs [refer to The incidence and severity of NAS varies depending on the type of drug. Some babies may have had in-utero exposure to multiple drugs. 
Incidence
Different definitions, screening, assessment and diagnostic tools used in different countries complicate the reporting of substance use 4 and the variety and subtlety of clinical presentation makes recognition difficult.
• In Queensland in 2007, the reported incidence of NAS in newborn babies was 0.3%, 5 however incidence may be higher than reported 3 • If screened some pregnant women who deny drug use may have positive urine screens for non-prescribed substances 6 • An Australian survey reported illicit drug use in 6% of women who were pregnant and/or breastfeeding in the preceding 12 months 7
• The IDEAL study in the United States reported 10.7% of mothers had used illicit drugs during pregnancy 8 • Alcohol use in Australia was reported in almost half of pregnant women and women who were breastfeeding up to 6 months postpartum. 9 In the USA, 4.5% of pregnant women reported binge drinking in the past month 
Antenatal care
The primary and most reliable method used to determine the extent of substance use during pregnancy which may help to identify babies at risk of NAS, is a structured maternal interview during antenatal assessment. • Women acutely affected by drugs (e.g. intoxication or acute withdrawal), will require further assessment. Management should include consultation with a drug and alcohol medical specialist 1
• Birth suite staff should be fully aware of the appropriate management protocol for women on an opioid treatment program
Pain relief
• The usual methadone/buprenorphine (subutex) dose will not provide any analgesia during labour 1
• Opioids including Pethidine, will be less effective in those receiving treatment with methadone or buprenorphine. Regional anaesthesia may be more appropriate in these women 1
• Women should be reassured that all routine pain relief will be offered during labour and this will be escalated when indicated or required 1
• Specialist consultation may be required for post-partum pain management (e.g. post caesarean section) The following immunisation should be given to babies 16 
:
• Hepatitis B immunoglobulin 100 IU (preferably within 12 hours of birth) and • Hepatitis B vaccination (preferably within 24 hours of birth, definitely within 7 days)
Inter-hospital transfer
At any time, if the birth facility is unable to provide an appropriate level of care, transfer the mother and baby to an appropriate higher level facility.
Once the decision has been made to transfer the baby to a higher level facility, this will be coordinated by Retrieval Services Queensland (RSQ) and a Neonatal medical coordinator, by calling 1300 799 127.
NAS assessment and diagnosis
A detailed maternal antenatal drug history is essential to identify babies at risk of developing NAS.
1,3
Withdrawal has been documented in babies even if methadone is stopped one month prior to birth (but not more).
1
Maternal factors that suggest an increased risk of fetal substance exposure and the onset of NAS include:
• inadequate antenatal care
• perinatal infections • previous unexplained intrauterine fetal death (IUFD)
• previous baby with NAS • placental abruption 2, 17 Neonatal factors that are known to be associated with maternal drug use include:
• low birth weight 1
• intrauterine growth restriction (IUGR) 1
• unexplained prematurity 1,2,18
Onset of withdrawal
Onset of withdrawal symptoms varies and is dependent on the:
• dose • half-life and • timing of last drug dose prior to birth Exposure to some substances (e.g. cocaine, alcohol) close to the time of birth may result in signs of neonatal intoxication.
Withdrawal from:
• heroin may be clinically apparent within 24 hours from birth but is usually observed between 24 and 72 hours • methadone/buprenorphine may be delayed until 3 -7 days after birth, or beyond • SSRI/SNRI is variable in onset and may occur within 2 days of birth 12 , but may not begin until late in the first week of life
Clinical presentation:
Clinical presentation of NAS is non-specific. If maternal drug history is unknown, it may not be suspected. Clinical presentation depends on many factors including:
• maternal dose There is no consistent relationship between maternal methadone dose and the incidence or severity of NAS. 3 However evidence is emerging that indicates the incidence of NAS increases with higher maternal doses. 20 [refer to Table 3 
System
Signs and symptoms
Central nervous system
• Tremors
• Irritability 
Differential diagnosis
Due to the non-specific nature of the signs and symptoms of drug withdrawal in the baby, it may be difficult to differentiate NAS from other neonatal conditions such as:
NAS may present with seizures. In this event, always consider other causes for neonatal seizures.
Even • fetal opioid exposure can be detected after the first trimester by meconium analysis 21 • obtain maternal consent 1 3
Measuring NAS
At the onset of any signs or symptoms that may be consistent with NAS, a detailed assessment using a validated assessment tool helps to determine which babies have NAS. 1 Regardless of the assessment tool chosen, use of an abstinence scoring sheet provides more objective criteria to determine 2 :
• when pharmacological treatment is necessary • whether a drug dose should be increased or decreased Training staff in the use of the assessment tool is essential to increase reliability and scoring consistency. 
Finnegan and Modified Finnegan Neonatal Abstinence Severity Score
The Finnegan and Modified Finnegan Neonatal Abstinence Severity Score (Finnegan score) is the most widely used tool for assessing NAS and is recognised as an Australian standard. The Finnegan scoring system is dynamic. Assessment is not of a single time point, scores should reflect all the symptoms observed between scoring times. Assessment by a consistent care giver (health professional and mother) helps to increase scoring accuracy and subsequent treatment 24 Perform scores ½ to 1 hour after feeds. Do not wake a sleeping baby for assessment Suspect NAS and investigate to determine diagnosis in any baby that:
• is unsettled • is irritable • has a high pitched cry • has tremors/jitteriness • does not feed well and/or has diarrhoea If a baby is transferred to a special care nursery for clinical assessment following the onset of symptoms he/she may be returned to the postnatal ward following an appropriate period of observation if he/she does not require medication.
Preterm babies
• may have less severe symptoms of withdrawal from opioid exposure • the onset is likely to be later • symptoms may be confused with other manifestations of prematurity • risks of environmental tobacco smoke exposure
Supportive therapy
Non-pharmacological management is the first line of treatment for in-utero exposure to maternal substance use. 1,3,11 [refer to Appendix C: Supportive therapy for care of a baby with NAS, Appendix E: Baby stability and stress signals].
Environment
NAS heightens sensitivity to the external environment therefore, excessive noise, movement and lighting around babies' cots should be avoided.
Breastfeeding
In most cases, mothers who are drug dependent should be encouraged and supported to breastfeed 1 :
• breast milk may reduce the severity of NAS and the requirement for medication 28 o abrupt cessation of breastfeeding may precipitate NAS 29 • mothers who are Hepatitis C antibody positive should be encouraged to breastfeed however: o milk should be expressed and discarded if the nipples are cracked or bleeding.
1, 16, 30 [refer to Appendix F: Management and follow-up of babies of Hepatitis C infected mothers] Breastfeeding is rarely contraindicated, unless there is ongoing use of drugs such as heroin, cocaine or amphetamines or if the mother is HIV positive. 3 Babies with NAS have higher caloric requirements and feeding schedules should reflect this. Provide women with education and support to ensure appropriate feeding, with particular regard to:
• feeding on demand to help initiate and establish lactation • breast milk expression, particularly if the baby has a disorganised suck or fails to engage in nutritive sucking for a sufficient length of time • baby behaviour, which may indicate the need for increased feeding frequency or volume.
Increased feeding frequency is normal in the first few days after birth and it is important that this is not confused with the symptoms of withdrawal • the need for supplementary feeds of expressed breast milk or formula which may be required until adequate caloric intake is achieved 1
• baby's weight as an assessment of feeding and intake
• use of a dummy/pacifier 1 Consider referral to a lactation consultant or Child Health feeding support services for those with complex needs or where there are problems or concerns about breastfeeding. 
Formula feeding
Some women may choose to artificially feed their babies with infant formula. This may be the primary source of nutrition for the baby or provided in conjunction with breastfeeding. Women who choose to artificially feed their babies should be given education and information regarding:
• preparation, transport and storage of (reconstituted/powdered) infant formula 
Pharmacological therapy
[refer to Table 4 . Morphine dosing and weaning schedule and • Use of an opioid is recommended for treatment of NAS due to in-utero opioid exposure o Morphine is the opioid of choice [1] [2] [3] 11, 32, 33 • Phenobarbitone is the preferred treatment for non opioid NAS 11 and should be primarily prescribed for withdrawal from: o non opioid central nervous system (CNS) depressants (eg. benzodiazepines, alcohol, barbiturates) or o SSRI/SNRI exposure • Phenobarbitone may be used in conjunction with morphine where: o symptoms of NAS related to opioid exposure are not adequately suppressed or remain uncontrolled on the maximum morphine dose (1 mg/kg/day) or o NAS is due to in-utero poly drug exposure • Reduction in medication dosage should only be considered when there has been 48 -72 hours of clinical stability with Finnegan scores below treatment levels
Morphine
Morphine is the drug of choice for opioid withdrawal [refer to Table 4 . Morphine dosing and weaning schedule]. Continue Finnegan scores for 72 hours after ceasing morphine
Dosing of the vomiting baby
Reduce the risk of the baby vomiting the morphine dose by:
• giving the dose before a feed • ensuring the baby is not overfed
If the baby has a large vomit within 5 -10 minutes of receiving the morphine dose, repeat the dose
Phenobarbitone
Phenobarbitone should be the initial medication chosen for medical management of non-opioid withdrawal 1,2,11 [refer to Table 5 . Phenobarbitone dosing and weaning schedule]. 
Phenobarbitone is the preferred treatment for non opioid related NAS 11 and should be used as an initial treatment if babies with signs of NAS reach treatment threshold and 1 :
• maternal drugs used are unknown
• maternal drugs used are non-opioid
• the mother was intoxicated with alcohol or non-opioid drugs at the time of birth 
Weaning phenobarbitone
• Reduce phenobarbitone dose by 10 to 20% when baby's Finnegan scores are consistently less than 8 (when scored every 4 -6 hours) for 72 hours • Dose reductions should not occur more often than every 72 hours
Dosing of the vomiting baby
Reduce the risk of baby vomiting the phenobarbitone dose by:
• giving the dose before a feed
• ensuring baby is not overfed
If the baby has a large vomit within 5 -10 minutes of receiving the phenobarbitone dose, it is appropriate to repeat the dose
6
Discharge planning
Consider and review ongoing needs using a multidisciplinary approach prior to hospital discharge. This may be informed by any antenatal psychosocial assessment performed by a midwife or social worker. The potential for negative outcome increases in the presence of cumulative risk factors. 34 An individual discharge plan for mother and baby (a written plan assists with accurate information transfer) should be developed incorporating a multidisciplinary approach with referral to appropriate community services including: 
Length of stay
Recommended length of stay is dependent on in-utero substance exposure:
• Opioid exposed babies should not be discharged before Day 7. The onset of symptoms of withdrawal from opioid exposure may be delayed for several days, particularly in breastfed babies 28 • Non opioid exposed babies may be considered for discharge from Day 5 if appropriate follow up is arranged 
Criteria for discharge
Discharge from hospital will be considered when the baby is:
• clinically stable • feeding well and has begun to gain weight Child protection concerns should be considered in the presence of:
• continued intravenous or illicit drug use • suspected baby neglect • suspected domestic violence • any other issues identified by Social Work assessment Establish a safety action plan that may be implemented in the event that parent(s) involved with DoC (CSS) fail to engage with community services.
Home medication
A well coordinated outpatient discharge plan is required before discharge on medication is considered. This may be appropriate if the:
• multidisciplinary psychosocial assessment has been completed and the team agree that the safety of the baby can be assured 1
• baby is term and healthy and the primary reason for hospitalisation was NAS • baby is tolerating full sucking feeds • baby is gaining weight • baby is considered to be stable on medication and has already tolerated a dose reduction (i.e. no increase in symptoms in the 72 hours following reduction). In the case of a baby receiving morphine, discharge should not be considered unless the daily dose is less than (<) 0.5 mg/kg/day • parent(s)/carers are able to administer medication 1
• required support and follow-up has been arranged and parent(s) have received education on: o apnoea recognition and management o cardiopulmonary resuscitation and emergency contacts o reducing the risk SIDS/SUDI. 1,26 SIDS is more common in babies exposed to opioids in pregnancy 3 o safe sleeping practices 1, 26, 27 o medication: administration, signs of toxicity and action to be taken in this situation storage and safety baby vomiting following dose administration o NAS withdrawal symptoms
Follow-up
Babies who required monitoring and/or medication for management of NAS should receive:
• Medical review within one week of discharge
Withdrawal symptoms may continue after discharge and after medication ceases (e.g. hypertonicity and poor feeding). Parent(s) should be encouraged to engage with community services (e.g. GP, Child Health) to access support and guidance.
Babies discharged whilst still receiving medication require:
• hospital clinic follow-up at least weekly until after the medication has been ceased 
Mild tremors when disturbed
Baby exhibits observable tremors of the hands or feet whilst being handled.
Moderate to severe tremors when disturbed
Baby exhibits observable tremors of the arm/s or leg/s with or without tremors of the hands or feet whilst being handled.
Mild tremors when undisturbed
(Undisturbed tremors should be assessed by observing the baby for at least 2 oneminute undisturbed periods). Baby exhibits observable tremors of the hands or feet whilst undisturbed. Moderate to severe tremors when undisturbed Baby exhibits observable tremors of the arm/s or leg/s with or without tremors of the hands or feet whilst undisturbed.
Increased muscle tone
Should be assessed when the baby is awake but not crying. There is tight flexion of the baby's arms and legs (unable to slightly extend the arms or legs).
Excoriation
If occurs on chin, knees, cheeks, elbow, toes or nose. Score only when excoriations first appear, increase or appear in a new area. Does not include excoriated nappy area caused by loose stools.
Myoclonic jerks
The baby exhibits twitching movements of the muscles of the face or extremities or if jerking movements of the arms or legs are observed.
Central nervous system disturbances

Generalised convulsions
Generalised activity involving tonic (rigid) extensions of all limbs (but may be limited to just one limb), or manifested by tonic flexion of all limbs. Generalised jitteriness of extremities is observed. Hold or flex the limbs, if the jitteriness does not stop it is a seizure. If subtle seizures are present (eye staring, rapid eye movements, chewing, fist clenching, back arching, cycling motion of limbs with or without autonomic changes) then they should be scored in this category.
Excessive sucking
The baby shows increased (greater than 3 times) rooting (turns head to one side searching for food) while displaying rapid swiping movements of hand across mouth prior to or after a feed.
Poor feeding
The baby demonstrates excessive sucking prior to a feed, yet sucks infrequently during feeding, taking small amounts and/or demonstrates an uncoordinated sucking reflex. Also score if the baby continuously gulps the milk and stops frequently to breathe. Regurgitation
Regurgitation not associated with burping occurs 2 or more times during a feed. Projectile vomiting 1 or more projectile vomiting episode occurring during or immediately after a feed. Loose stools Scored if stool which may or may not be explosive, is curdy or seedy in appearance. A liquid stool, without a water ring on the nappy should also be scored as loose. • Share eye contact and let baby look at your face management Depression and other mood disorders occur in approximately 10% of pregnant women, and depression during pregnancy may be associated with an increased risk of preterm birth, low birth weight, operative birth and admission of the newborn to neonatal intensive care units. 36 SSRI/SNRIs have become the drugs of choice for the treatment of depression and other mood and behavioural disorders such as obsessive-compulsive disorder, panic disorder and anxiety disorders. 37 Frequent use of these drugs during pregnancy and the concerns regarding neonatal complications have resulted in a labelling caution (neonatal behavioural syndrome) associated with pregnancy exposure.
Gastrointestinal disturbances
38
Maternal effects:
• occur as a result of either discontinuation (withdrawal) or toxicity (excess of 5-HT)
• symptoms of discontinuation syndrome are primarily subjective and may:
o occur within a few days of cessation, probably due to a hypo-serotonergic state o include headache, dizziness, nausea, tiredness, anxiety and low mood • symptoms of toxicity syndrome are primarily objective and may:
o include mental state changes (agitation, confusion), neuromuscular hyperactivity (tremor, myoclonus, rigidity, hyperreflexia), and autonomic hyperactivity (fever, sweating, tachycardia, tachypnoea)
Neonatal effects:
• Evidence of adverse symptoms in babies born to mothers prescribed SSRIs during pregnancy from multiple case reports, adverse drug reaction reports including WHO database analysis, and prospective studies 36 • Neonatal behavioural symptoms may occur in up to 30% of SSRI-exposed babies 12, 35, 38 :
o Symptoms may be consistent with a severe NAS (Finnegan score ≥ 8) 12, 38 o Timing and intensity of neonatal symptoms is influenced by maternal dose 12 and duration of treatment o Peak of intensity of symptoms usually on Day 2 12 , but onset may not begin until 5 to 7 days. Mild symptoms and signs may continue for 2 to 4 weeks o Most frequently observed symptoms include 12 : tremor, gastrointestinal or sleep disturbance, hypertonicity, and high-pitched cry transient seizures have been reported 12, 38 o No neonatal deaths attributable to late-pregnancy SSRI exposure reported • An association has been found between SSRI exposure in late pregnancy and persistent pulmonary hypertension in the newborn (PPHN) 36, 39 and neonatal hypoglycaemia 1, 12, [40] [41] [42] • Observed symptoms in some cases such as jitteriness, tachypnoea, hypertonicity, temperature instability and diarrhoea can be attributed to serotonergic hyperstimulation (toxicity) 12 : o Differentiation between toxicity and discontinuation syndrome as cause of symptoms presents a dilemma for clinicians 43 and may not be possible on clinical grounds, although symptoms due to toxicity are likely to be present immediately from birth o Drug levels of SSRIs with short half-lives (paroxetine) may be high enough at birth to cause toxicity, and decline rapidly enough to produce symptoms of withdrawal • Significant or prolonged withdrawal symptoms may require specialised management including: o fluid replacement o sedative (phenobarbitone) or anti-convulsant therapy
Prevention and management
• Consider maternal dose reduction in late third trimester to reduce the risk of neonatal effects. This must be approved and supervised by Psychiatric team • Discuss SSRI/SNRI-related neonatal behavioural syndrome antenatally with pregnant women 12, 43 • Encourage Breastfeeding 12 • Manage baby similarly to opioid exposed babies. 12 A minimum of 3 days postnatal observation is recommended 35 
